Blood stored longer may be less safe for patients with massive blood loss and shock
(University of Alabama at Birmingham) In a collaborative study using a mouse model, researchers have found mechanistic links between older stored red blood cell transfusions and subsequent bacterial pneumonia. This may reveal new approaches to improve safety of stored red blood cell transfusions. The key player is free heme, a breakdown product from degraded red blood cells (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2018 Category: International Medicine & Public Health Source Type: news
Nerve cells found to suppress immune response during deadly lung infections
(Harvard Medical School) Neurons that carry nerve signals to and from the lungs suppress immune response during fatal lung infections with the bacterium Staphylococcus aureus.Animal experiments show that disabling these neurons can boost immune response and promote bacterial clearance to aid recovery.Targeting neuro-immune signaling in the lungs can pave the way to nonantibiotic therapies for bacterial pneumonia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 5, 2018 Category: Infectious Diseases Source Type: news
FDA Approves AVYCAZ(R) (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
First Gram-Negative Antibiotic Approved in the U.S. to Treat HABP/VABP in Over 15 Years
DUBLIN, Feb. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. F... Biopharmaceuticals, FDA Allergan, AVYCAZ, ceftazidime, avibactam, Bacterial Pneumonia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 2, 2018 Category: Pharmaceuticals Source Type: news
FDA Approves Avycaz (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
DUBLIN, Feb. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Allergan ' s supplemental New Drug Application (sNDA) to expand the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 1, 2018 Category: Drugs & Pharmacology Source Type: news
Pneumonia: Treatment with vaccines instead of antibiotics
(University of Zurich) A properly functioning immune system is key to resolve bacterial pneumonia. Researchers from the University Children's Hospital Zurich and UZH working with an international team have now found that specific immune cells are crucial for recovery. The researchers' work paves the way for developing new vaccines, which would also counteract the emerging resistance to antibiotics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 21, 2017 Category: International Medicine & Public Health Source Type: news
More Laboratory Tests Performed at Major Teaching Hospitals
More tests per day for bacterial pneumonia, cellulitis at major teaching versus nonteaching hospitals (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 14, 2017 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Infections, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pulmonology, Journal, Source Type: news
Paratek reports positive data from Phase III trial of omadacycline
Paratek Pharmaceuticals has reported positive safety and efficacy data from a Phase III clinical trial (OPTIC) of its investigational antibiotic, omadacycline, for community-acquired bacterial pneumonia (CABP). (Source: Drug Development Technology)
Source: Drug Development Technology - October 8, 2017 Category: Pharmaceuticals Source Type: news
US FDA grants priority review status to Allergan ’s sNDA for Avycaz
The US Food and Drug Administration (FDA) has granted priority review status for Allergan ’s supplemental New Drug Application (sNDA) for Avycaz (ceftazidime and avibactam) to treat hospital-acquired bacterial pneumonia / ventilator-associated bacteri… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 2, 2017 Category: Pharmaceuticals Source Type: news
Nabriva's Pneumonia Drug Succeeds in Late-stage Trial Nabriva's Pneumonia Drug Succeeds in Late-stage Trial
Nabriva Therapeutics Plc has reported that its experimental antibiotic for community-acquired bacterial pneumonia (CABP) met the main goal of a late-stage study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Nabriva's pneumonia drug succeeds in late-stage trial, shares soar
(Reuters) - Nabriva Therapeutics Plc shares more than doubled in premarket trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia met the main goal of a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Nabriva's pneumonia drug meets main goal in late-stage study
(Reuters) - Nabriva Therapeutics Plc said on Monday its experimental treatment for community-acquired bacterial pneumonia met the main goal in a late-stage study, sending its shares up more than 70 percent in premarket trading. (Source: Reuters: Health)
Source: Reuters: Health - September 18, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Researchers identify changes in lung cells following infections
When people develop a respiratory infection, recovery from their illness leaves behind an immunological memory that influences how they will respond to later infections. In a new study, researchers demonstrate for the first time that recovery from bacterial pneumonia changes the tissue that was infected, seeding the lungs with immune cells called resident memory T (TRM) cells. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 17, 2017 Category: Science Source Type: news
Researchers identify changes in lung cells following infections
(Boston University Medical Center) When people develop a respiratory infection, recovery from their illness leaves behind an immunological memory that influences how they will respond to later infections. In a new study, researchers demonstrate for the first time that recovery from bacterial pneumonia changes the tissue that was infected, seeding the lungs with immune cells called resident memory T (TRM) cells. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 17, 2017 Category: Infectious Diseases Source Type: news
Antibiotic developer's stock soars 23% thanks to positive study data
Paratek Pharmaceuticals, a Boston biotech company that has rapidly expanded its presence in the Philadelphia suburbs, saw its stock price soar by 23 percent Tuesday after posting positive results from late-stage testing of its lead new drug candidate.
The study showed omadacycline, its experimental oral and IV antibiotic, met all the clinical trial's primary and secondary endpoints in treating patients with community-acquired bacterial pneumonia.
Paratek's stock closed up 23 percent at $22.85 per… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 4, 2017 Category: Biotechnology Authors: John George Source Type: news
Antibiotic developer's stock soars 23% thanks to positive study data
Paratek Pharmaceuticals, a Boston biotech company that has rapidly expanded its presence in the Philadelphia suburbs, saw its stock price soar by 23 percent Tuesday after posting positive results from late-stage testing of its lead new drug candidate.
The study showed omadacycline, its experimental oral and IV antibiotic, met all the clinical trial's primary and secondary endpoints in treating patients with community-acquired bacterial pneumonia.
Paratek's stock closed up 23 percent at $22.85 per… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 4, 2017 Category: American Health Authors: John George Source Type: news
